Skip to main content
SpringerLink
Log in

The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

In order to determine if prior use of exogenous estrogens was related to the estrogen receptor (ER) content of primary breast cancers, a retrospective analysis was performed from 536 patients with invasive breast cancer. The patient's age, menopausal status, oral contraceptive or estrogen replacement therapy usage, and the ER and progesterone receptor (PR) content of the breast cancer were recorded for all patients. Hormone usage in premenopausal and postmenopausal patients was compared to ER and PR levels in primary breast cancers using non‐parametric testing. Complete information was available from 508 (193 premenopausal and 315 postmenopausal) patients. Breast cancers were ER positive in 72% of postmenopausal patients and 57% of premenopausal patients. The majority of patients received 'Some' form of hormone therapy (111 of 193 premenopausal patients and 233 of 315 postmenopausal patients). Significantly more estrogen receptors were detected in tumors from patients receiving 'some' estrogen therapy compared to 'never' users. Postmenopausal patients 'never receiving estrogen therapy had a lower rate of ER positive tumors (62%) compared to 'some' users (75% χ2=4.99, p<0.05). The same relationship was seen for PR ('never' users 44% positive, 'some' users 58% positive, χ2=5.19, p<0.05). We conclude that postmenopausal patients who received 'some' estrogen therapy are more likely to have breast cancers that are estrogen receptor and progesterone receptor positive.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo, UB: Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 130(2): 221–228, 1989

    Google Scholar 

  2. Gambrell RD: The role of hormones in the etiology of breast and endometrial cancer. Acta Obstetricia et Gynecologica Scandinavica - Suppl 88: 73–81, 1979

    Google Scholar 

  3. Hunt K: Breast cancer risk and hormone replacement therapy: a review of the epidemiology. Int J Fert Menopausal Stud 39 Suppl 2: 67–74, 1994

    Google Scholar 

  4. Henderson BE, Ross RK, Pike MC: Hormonal chemoprevention of cancer in women. Science 259(5095): 633–638, 1993

    Google Scholar 

  5. Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2(10): 1102–1109, 1984

    Google Scholar 

  6. Osborne CK, Yochmowiz MG, Knight WA, 3rd, McGuire WL: The value of estrogen and progesterone regimens in the treatment of breast cancer. Cancer 46: 2884–2888, 1980

    Google Scholar 

  7. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117(12): 1016–1037, 1992

    Google Scholar 

  8. Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist, L: Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Intern Med 113(2): 95–103, 1990

    Google Scholar 

  9. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE: A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 313: 1044–1049, 1985

    Google Scholar 

  10. Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, Escher G, Lippman M, Savlov E, Wittliff J, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotheraphy in primary breast cancer. J Clinical Oncology 1(4): 227–241, 1983

    Google Scholar 

  11. Zumoff B: Biological and endocrinological insights into the possible breast cancer risk from menopausal estrogen replacement therapy. Steroids 58(5): 196–204, 1993

    Google Scholar 

  12. Lacassagne A: Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer 27: 217–228, 1936

    Google Scholar 

  13. Suntzeff V, Burns EL, Loeb L: The effect of injections of estrin on the incidence of mammary cancer in various strains of mice. Am J Cancer 27: 229–245, 1936

    Google Scholar 

  14. Lippman ME, Bolan G. Oestrogen-responsive human breast cancer in long term tissue culture. Nature 256(5518): 592–593, 1975

    Google Scholar 

  15. Buring JE, Hennekens CH, Lipnick RJ, Willett W, Stampfer MJ, Rosner B, Peto R, Speizer FE: A prospective cohort study of postmenopausal hormone use and risk of breast cancer in U.S. women. Am J Epidemiol 125: 939–947, 1987

    Google Scholar 

  16. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW: The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 257(2): 209–215, 1987

    Google Scholar 

  17. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C: The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321(5): 293–297, 1989

    Google Scholar 

  18. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S: Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 134(12):1375–1385; discussion 1396-, 1991

    Google Scholar 

  19. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S: Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study. Am J Epidemiol134(12): 1386–1395; discussion 1396-, 1991

    Google Scholar 

  20. Colditz GA, Stampfer MJ, Willett WC, Hennekens CH, Rosner B, Speizer FE: Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 264(20): 2648–2653, 1990

    Google Scholar 

  21. Brinton LA, Hoover R, Fraumeni JFJ: Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 54: 825–832, 1986

    Google Scholar 

  22. Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NH, Sparano JA, DC, Wood WC: Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA 272(7): 540–545, 1994

    Google Scholar 

  23. Dupont WD, Page DL: Menopausal estrogen replacement therapy and breast cancer. Archives of Internal Medicine 151(1): 67–72, 1991

    Google Scholar 

  24. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265(15): 1985–1990, 1991

    Google Scholar 

  25. Armstrong BK: Oestrogen therapy after the menopause-boon or bane? Med J Aust 148: 213–214, 1988

    Google Scholar 

  26. Grady D, Ernster V: Invited commentary: does postmenopausal hormone therapy cause breast cancer? Am J Epidemiol 134: 1396–1400, 1991

    Google Scholar 

  27. Leather AT, Holland EF, Studd JW: The clinical problems of women currently referred to a specialist menopause clinic. J Royal Soc Med 86(7): 385–387, 1993

    Google Scholar 

Download references

Authors
  1. Elyse E. Lower
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robbin Blau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paula Gazder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Donna L. Stahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lower, E.E., Blau, R., Gazder, P. et al. The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer. Breast Cancer Res Treat 58, 205–210 (1999). https://doi.org/10.1023/A:1006315607241

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006315607241

Search

Navigation